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CONNECTEDCARE FOR MS: IMPACT OF MANAGED THERAPY ON ADHERENCE 
TO MULTIPLE SCLEROSIS MEDICATIONS  
Staskon F1, Clark B2, DuChane J2, Miller R3, Love K1, Duncan I2 
1Walgreens Co, Deerfield, IL, USA, 2Walgreen Co., Deerfield, IL, USA, 3Walgreens Co, Carnegie, 
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BACKGROUND: A large national retail pharmacy chain developed a patient-
centric program providing enhanced levels of monitoring and care for patients 
taking MS Specialty Drugs as dispensed in a retail setting. MS biologics covered 
in the ConnectedCare for Multiple Sclerosis (CCMS) program during this analysis 
period included Avonex, Betaseron, Copaxone, Extavia, and Rebif. OBJECTIVES: 
To compare adherence rates for MS biologics between managed and non-
managed patients new to retail pharmacy or the CCMS program. The effect of 
health complications on adherence rates was also assessed. METHODS: This was 
a retrospective analysis of MS patients new to therapy (or pharmacy chain) 
during the initial six months of CCMS. Patients were followed for one year. 
Adherence was measured using proportion of days covered (PDC). For the 
primary objective, propensity scores based on patients’ gender, age, presence of 
chronic comorbidities, and pre-study adherence to chronic medications were 
used to match the CCMS intervention group to a comparisons group. Sub-group 
analysis on health complications (chronic medication comorbidity, or 
assessment screenings for depression and fatigue) used Analysis of Covariance 
to adjust for the propensity variables when examining PDC in the presence of 
health complications across managed cohorts. RESULTS: Mean PDC was nearly 
10% higher for the managed CCMS patients than for non-managed patients. 
Patients not managed with at least one chronic comorbidity had about an 11% 
lower PDC than non-managed patients without a comorbid condition, whereas, 
managed patients indicated little difference in relation to the presence of a 
comorbidity. Adherence levels were also reduced for non-managed patients 
reporting fatigue and depression, yet self-reports of fatigue and depression did 
not significantly affect adherence levels among managed patients. 
CONCLUSIONS: The provision of medication therapy management for MS 
patients significantly increases adherence to MS biologic medications. Among 
non-managed patients, adherence is even further reduced among patients with 
fatigue and depression.  
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CLINICAL AND ECONOMIC BURDEN OF VETERAN ALZHEIMER'S DISEASE 
PATIENTS IN THE UNITED STATES: A REAL-WORLD EVALUATION  
Wang L1, Zhang J1, Li L1, Baser O2 
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OBJECTIVES: To assess the clinical and economic burden of Alzheimer’s disease 
in the U.S. veteran population. METHODS: Data from the Veterans Health 
Administration (VHA) Medical SAS Datasets was used to conduct a retrospective 
study (October 1, 2005 - May 31, 2012). Patients diagnosed with Alzheimer’s 
disease throughout the study period were identified using International 
Classification of Disease 9th Revision Clinical Modification (ICD-9-CM) diagnosis 
code 331.0. Health care resource utilization and costs were assessed in the 12-
month follow-up period, and clinical status was examined for the 12-month 
baseline period before disease identification. Major treatments during the 60 
days after disease identification were also studied. All descriptive statistical 
analyses were performed using SAS v9.3 software. RESULTS: A total of 54,161 
Alzheimer’s disease patients were identified in the VHA population during the 
study period. The most common comorbidities for Alzheimer’s disease patients 
were hypertension (n=14,387, 26.56%), followed by mental disorders (n=13,440, 
24.81%), diabetes (n=7,440, 13.74%) and memory loss (n=4,850, 8.95%). Other 
comorbidities included senile dementia and hearing loss. The top three 
treatments for Alzheimer’s disease were donepezil hydrochloride (n=16,526, 
30.51%), simvastatin (n=16,010, 29.56%), and memantine (n=11,081, 20.46%). 
Outpatient services were utilized by 98.62% of Alzheimer’s patients, followed by 
pharmacy (86.75%) and inpatient visits (30.29%). Outpatient ($7,650, [standard 
deviation] SD=$12,539), pharmacy ($1,660, SD=$2,688), and inpatient costs 
($16,790, SD=$75,963) contributed to follow-up health care expenditures. 
CONCLUSIONS: The U.S. veteran Alzheimer’s disease patient population had 
high percentages of comorbid conditions, including hypertension and mental 
disorders, as well as outpatient and inpatient visits. Further analysis is needed to 
evaluate the extent to which the treatment of Alzheimer’s disease is complicated 
by the presence of these comorbidities.  
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COMORBIDITIES AND ECONOMIC BURDEN OF MULTIPLE SCLEROSIS PATIENTS 
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OBJECTIVES: To examine the comorbidities and economic burden of patients 
diagnosed with multiple sclerosis (MS) in the U.S. veteran population. METHODS: 
The study sample was extracted from the Veterans Health Administration (VHA) 
Medical SAS datasets from October 1, 2005 through May 31, 2012. All patients 
diagnosed with MS throughout the study period were identified using 
International Classification of Diseases 9th Revision Clinical Modification (ICD-9-
CM) diagnosis code 340.xx. Comorbid conditions were assessed for the 1-year 
baseline period before the MS identification date, and health care utilization and 
costs were assessed for 1 year of follow-up after the identification date. 
Statistical analyses were performed using SAS v9.3 software. RESULTS: There 
were 9,798 MS patients from 2005 to 2012 in the U.S. veteran population. The 
most frequent comorbidity for MS patients was hypertension (15.04%). All other 
comorbidities, including among others diabetes, depressive disorder, and 
lumbago, had frequencies of less than 10%. Common treatment medications for 
MS were simvastatin, omeprazole, lisinopril, and gabapentin. A total of 9,724 
(99.24%) MS patients had outpatient visits, while 8,471 (86.46%) patients had 
pharmacy visits and 1,976 (20.17%) inpatient visits. Outpatient, pharmacy and 
inpatient costs were $11,349 (standard deviation [SD]=$19,068), $3,220 
(SD=$7,285), and $9,171 (SD=$57,129), respectively. CONCLUSIONS: MS treatment 
is complicated by the presence of comorbidities. Further analysis in the context 
of complicated comorbid condition diagnoses is required to improve the overall 
burden of illness of MS patients.  
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VALIDATION OF A CHINESE VERSION OF NEUROPSYCHIATRY UNIT COGNITIVE 
ASSESSMENT TOOL (NUCOG)  
Gao L1, Walterfang M2, Velakoulis D2, Li SC1 
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OBJECTIVES: To validate a Chinese version of NUCOG METHODS: Accepted 
translation procedures were followed to develop a Chinese version of NUCOG. 
Patients from two hospitals were recruited between July and October, 2012. 
Statistical analysis was performed using SPSS 20.0. Subgroup analysis according 
to diagnosis was performed. Receiver Operating Characteristic (ROC) curves were 
utilized to test criterion validity. Convergent validity was assessed via 
correlations between NUCOG and MMSE and internal consistency was measured 
to test the reliability. RESULTS: 529 subjects comprised of patients with epilepsy 
(n=144), neurological diseases (n=81), dementia (n=44), control group (n=260) 
completed NUCOG and MMSE. Overall, both NUCOG and MMSE scores differed 
significantly across four groups with dementia<epilepsy=neurology<controls 
(p<0.0001). The subscale-by-group analysis of NUCOG indicated different 
cognitive patterns for four groups, with patient groups scoring lowest in memory 
and executive domains. All the four groups achieved higher scores in the 
language domain than in other domains. The NUCOG, but not the MMSE, 
discriminated between patients with simple partial and secondary 
generalized/tonic-clonic generalized seizures, stroke and Transient Ischemic 
Attack (TIA). Compared to the MMSE, the NUCOG exhibited higher area under 
the ROC curve (0.969 vs. 0.915) to detect dementia among patients. A premium 
cutoff score of 70.5 gave a sensitivity of 0.955 and specificity of 0.875 to detect 
dementia in the patient groups for NUCOG. The convergent validity was 
substantially correlated across entire sample, with Spearman’s r of 0.787 
(p<0.0001). Internal consistency of NUCOG by Cronbach’s α was 0.922. 
CONCLUSIONS: The Chinese version of NUCOG was demonstrated to be a 
sensitive, reliable screening tool for cognitive impairment. NUCOG could also 
better differentiate patients with certain seizure types, stroke and TIA compared 
to the MMSE. This would potentially expand the clinical usefulness of NUCOG in 
enabling clinicians to measure the cognitive profile of patients with epilepsy and 
ischemic cerebrovascular diseases.  
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PREDICTING THE LONG-TERM CLINICAL EFFECTIVENESS OF DACLIZUMAB IN 
RELAPSING-REMITTING MULTIPLE SCLEROSIS: A NEW MODELING 
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Guo S1, Hernandez L1, Saint-Laurent Thibault C1, Proskorovsky I2, Phillips GA3 
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OBJECTIVES: SELECT, a one-year phase II randomized controlled trial (RCT), 
showed benefits for daclizumab high-yield process 150mg (DAC HYP) versus 
placebo on relapses and disability among patients with relapsing-remitting 
multiple sclerosis (RRMS). This analysis utilized discrete-event simulation (DES) 
to model the potential long-term clinical implications of this trial. METHODS: An 
RRMS DES model that predicts the course of relapses, disability 
progression/regression, conversion to secondary-progressive MS (SPMS), and 
death was developed. During the RR phase, the occurrence of relapses could lead 
to change in patient’s Expanded Disability Status Scale (EDSS) scores, which in 
turn influences the risk of relapses. Both endpoints are predicted based on 
treatment and other predictors using two interrelated equations derived from 
four RCTs of RRMS patients (n=4,189), including SELECT, AFFIRM, CONFIRM, and 
DEFINE. Treatment can be stopped for various reasons and was assumed to have 
no residual effect at discontinuation. Conversion to SPMS or death could occur at 
any time and are predicted based on patient’s EDSS scores and other relevant 
characteristics using published epidemiological data. RESULTS: Over 20 years, 
patients on DAC HYP were predicted to result in: i) fewer relapses per patient (5.1 
vs. 7.2); ii) a higher proportion of patients free of any relapse (24% vs. 16%); iii) a 
lower percent of patients progressing to SPMS (69% vs. 74%), and iv) more time 
spent in less severe disability states (15.1 vs. 14.3 years in EDSS<7) compared to 
those without treatment. Life expectancy was also longer for patients on DAC 
HYP, but the difference was small. These outcomes were most sensitive to model 
time horizon. CONCLUSIONS: Long-term modeling based on the SELECT trial 
outcomes suggests that DAC HYP has a positive impact on key outcome 
measures of interest to patients with RRMS and their clinicians. Evidence from 
its phase III trial is still needed to support its use.  
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OBJECTIVES: To report the effect of BG-12 (dimethyl fumarate) in reducing the 
number of relapses requiring intravenous (IV) steroids and multiple sclerosis 
(MS)-related hospitalizations from a pre-specified integrated analysis of DEFINE 
and CONFIRM, which was designed to estimate–more precisely–the therapeutic 
effect of BG-12 versus placebo. METHODS: Eligible patients were aged 18–55 
years with relapsing–remitting MS (McDonald criteria) and an Expanded 
Disability Status Scale score of 0–5.0. Patients who received oral BG-12 240 mg 
twice (BID) or three times daily (TID) or placebo were included and the integrated 
analysis was to be conducted only if baseline characteristics and treatment 
effects were similar between the studies. Numbers of relapses requiring IV 
steroids and MS-related hospitalizations (tertiary endpoints in DEFINE and 
CONFIRM) were assessed. RESULTS: The integrated analysis included 769, 761, 
and 771 patients who received BG-12 BID, TID, and placebo, respectively. 
Baseline characteristics and treatment effects were generally similar between 
DEFINE and CONFIRM. There were significantly fewer relapses requiring steroids 
and MS-related hospitalizations in both BG-12 groups compared with placebo. 
BG-12 reduced the annualized rate of relapses requiring IV steroids by 48% (BID; 
rate ratio, 0.52 [95% confidence interval, 0.43–0.64]) and 50% (TID; 0.50 [0.41–0.61]) 
versus placebo (both p<0.0001) and reduced the annualized rate of MS-related 
hospitalizations by 34% (BID; 0.66 [0.47–0.92]; p=0.0146) and 47% (TID; 0.53 [0.37–
0.75]; p=0.0004) at 2 years. CONCLUSIONS: BG-12 significantly reduced the 
number of relapses requiring IV steroids and MS-related hospitalizations, which 
suggests benefits with regard to patient burden and health economic savings due 
to decreased resource utilization. These findings further support the efficacy 
results of DEFINE and CONFIRM.  
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THE EFFICACY AND TOLERABILITY OF PERAMPANEL COMPARED TO OTHER 
ADJUNCTIVE RECENTLY APPROVED ANTI-EPILEPTIC DRUGS (AEDS) FOR THE 
TREATMENT OF REFRACTORY PARTIAL ONSET SEIZURES: A SYSTEMATIC 
REVIEW AND BAYESIAN NETWORK META-ANALYSIS (NMA)  
Tongbram V1, Khan N1, Shah D1, Fortier KJ1, Hawkins N2 
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OBJECTIVES: Perampanel (PER) is the first orally active α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist approved for the 
adjunctive treatment of partial-onset seizures in patients with epilepsy aged 12 
years and older. While the regulatory approval was on the basis of 3 RCTs, which 
demonstrated the efficacy and acceptable safety of perampanel relative to 
placebo, for the purpose of funding and health technology assessment decisions 
comparisons to other similar AED are necessary.The aim is to compare the 
clinical efficacy and tolerability of PER relative to other recently approved AEDs 
(lacosamide (LCM), retigabine (RTG), and eslicarbazepine (ESL)) for the adjunctive 
treatment of partial onset seizures with or without secondarily generalization. 
METHODS: A systematic literature review was conducted to identify all RCTs of 
PER and selected AEDs. EMBASE, MEDLINE, and the Cochrane Central Register of 
Controlled Trials from 1998 to September 2011, abstracts from selected 2010 and 
2011 conferences, reference lists of included studies and unpublished study 
reports were searched. The odds-ratio for three outcomes: “>50% reduction in 
seizure frequency”, “seizure freedom” and “withdrawal due to adverse events” 
were estimated using fixed- and random-effects Bayesian NMA models. 
RESULTS: Twelve RCTs (3 PER, 3 LCM, 3 RTG and 3 ESL) met the inclusion criteria. 
In the analysis for “>50% reduction in seizure frequency”, all AEDs performed 
significantly better than placebo with odds-ratio for PER being similar to the 
other comparators. In the analysis for “seizure freedom”, all AEDs except LCM 
performed significantly better than placebo. In the analysis for “withdrawal due 
to adverse events” PER had the lowest odds-ratio compared to other AEDs. No 
significant difference was observed in any of the three outcomes between PER 
and the other AEDs when compared against each other. CONCLUSIONS: 
Compared with other licensed adjunctive AEDs, perampanel offers similar 
clinical efficacy and tolerability profile.  
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OBJECTIVES: To report efficacy of BG-12 (dimethyl fumarate) in pre-specified 
patient subgroups stratified by age, gender, treatment history, prior relapses, 
Expanded Disability Status Score (EDSS), McDonald criteria, T2 lesion volume, 
and presence/absence of gadolinium-enhancing lesions at baseline in a pre-
specified integrated analysis of DEFINE and CONFIRM. This analysis was 
designed to estimate–more precisely–the treatment effect of BG-12 versus 
placebo. METHODS: Eligible patients were aged 18–55 years with a diagnosis of 
relapsing-remitting multiple sclerosis (RRMS) (McDonald criteria) and an EDSS 
score of 0–5.0. Patients receiving BG-12 240 mg twice (BID) or three times daily 
(TID) or placebo were included in this analysis. Primary endpoints were 
proportion of patients relapsed (DEFINE) and annualized relapse rate (ARR) 
(CONFIRM) at 2 years. Secondary endpoints included number of new/enlarging 
T2 lesions and disability progression. The pre-specified integrated analysis was 
to be conducted only if baseline characteristics and treatment effects were 
consistent between the studies. RESULTS: The integrated intent-to-treat 
population comprised 2,301 patients while MRI evaluations were performed in a 
cohort of 1,046 patients. Baseline characteristics and treatment effects were 
generally similar across studies. Both BG-12 BID and TID reduced ARR versus 
placebo at 2 years by approximately 50%, risk of relapse, number of 
new/enlarging T2 lesions, and risk of disability progression at 2 years versus 
placebo across the subgroups. For example, ARR versus placebo at 2 years was 
reduced by 50% (BID; rate ratio 0.50 [95% confidence interval 0.40–0.64]) and 53% 
(TID; 0.47 [0.37–0.60]) in patients with ≤1 relapse in the year before study entry 
and 47% (BID; 0.53 [0.40–0.72]) and 41% (TID; 0.59 [0.44–0.80]) in patients with ≥2 
relapses. CONCLUSIONS: These findings further indicate consistent efficacy of 
BG-12 on both clinical and neuroradiological measures across a wide spectrum of 
RRMS patients.  
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OBJECTIVES: Migraine is a public health problem that has an impact on both the 
individual sufferer and on society. The objective of this study was to examine 
the PCS (physical component summary) and MCS (mental component summary) 
score after being treated with one of the two different recommended level A 
medications – Triptans and Anti-epileptics. METHODS: MEPS data 2003-2010 
(with panel 9-14) were downloaded from the AHRQ website. Migraine patients 
who started to receive either Triptans or Anti-epileptics in round 3 were retained 
in the cohort. Patients who received combination therapy or received the 
medication in round 1 or 2 were excluded in order to control for the baseline 
characteristics. Propensity score method was used to ensure the patients being 
compared are equal within each tertile. The predicted probability of receiving 
Triptans was calculated for all patients in the cohort by using multiple logistic 
regression to control for demographics, comorbidity and PCS/MCS in round 2. 
The probabilities were then stratified into tertiles. The outcomes – PCS and MCS 
in round 4 were compared within each tertile to examine if there were any 
differences between the two medications. RESULTS: Overall there were 120 
patients in the cohort with weighted frequency of 2,779,074 (2,049,642 for 
Triptans and 729,432 for Anti-epileptics). After the propensity score stratification, 
all the baseline information between the two treatment cohorts were equal in 
each tertile except race in tertile 2 (p=0.0124). After the outcomes comparison, 
there were no differences in round 4 PCS and MCS score between the two 
medications for all three tertiles. CONCLUSIONS: Triptans are the most 
expensive among all the migraine medications. However, the findings of our 
study demonstrated there were no differences in PCS and MCS after the 
treatment. Future studies should examine different outcomes and see if Triptans 
can improve other clinical findings.  
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MULTIPLE SCLEROSIS EARLY TREATMENT RATES IN UNITED STATES 
VETERANS  
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OBJECTIVES: Multiple sclerosis (MS) is a common autoimmune demyelinating 
disease of the central nervous system. Early treatment of MS aids in repressing 
the most severe stage of acute axonal injury. The objective of this study was to 
characterize the proportion of MS patients who received early treatment, defined 
as an immunosuppressive treatment within 12 months following diagnosis. 
METHODS: We identified patients with an MS diagnosis who sought care in the 
US Veterans Health Administration (VHA) system from 1999-2010. The index 
date was the date of firs MS diagnosis. Patients who did not have at least 12 
months of follow-up time were excluded. Descriptive statistics were used to 
characterize prescriptions for medications commonly used to treat MS in the 12 
months following the index date. RESULTS: Our analysis cohort consisted of 
6,011 MS patients. Mean age was 53.8 (SD 13.4) years and 80.7% were male. Race 
was known in 40.8%; of which most were white (80.2%) or black (16.0%). Only 
35.3% of MS patients had a prescription for MS treatment in the 12 months 
following the index date. The most common MS treatments among MS patients 
were interferon beta 1a (13.2%), glatiramer (10.3%), amantadine (6.9%), 
prednisone (6.5%), and methylprednisolone (5.5%). Younger patients were more 
likely to have prescriptions. In a subset of 3,312 patients age <55, e.g., those who 
would be eligible for a clinical trial, 44.1% had a prescription for any 
immunosuppressive therapy used to treat MS. Interferon beta 1a (17.9%) was the 
most common treatment in this subgroup followed by glatiramer (13.6%), 
amantadine (8.9%), methylprednisolone (7.3%), and prednisone (6.8%). 
CONCLUSIONS: This descriptive analysis indicates that most patients with a 
diagnosis of MS do not receive early immunosuppressive therapy. Future 
research should identify relevant barriers to treatment and potential solutions to 
overcoming these barriers.  
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